Genetron Holdings Limited (GTH)
| Previous close | 1.4500 |
| Open | 1.4500 |
| Bid | 1.3800 x 800 |
| Ask | 1.3900 x 1800 |
| Day's range | 1.3400 - 1.4800 |
| 52-week range | 1.2500 - 22.7500 |
| Volume | |
| Avg. volume | 302,632 |
| Market cap | 122.643M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6960 |
| Earnings date | 23 Mar 2022 - 28 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.77 |
- GlobeNewswire
Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022
BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2022 on June 2, 2022 before the US market open. Management will host a conference call for invest
- Simply Wall St.
Do Institutions Own Genetron Holdings Limited (NASDAQ:GTH) Shares?
The big shareholder groups in Genetron Holdings Limited ( NASDAQ:GTH ) have power over the company. Institutions will...
- GlobeNewswire
Genetron Health Receives CE Mark for Human B Lymphocyte Minimal Residual Disease Detection Kit Seq-MRD®
BEIJING, April 19, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced it has received a CE Mark for its proprietary Human B Lymphocyte Minimal Residual Disease Detection Kit (Reversible Termination Sequencing Method), which is also known as Seq-MRD® (
